Torrent Pharma Ki Q3 Kamaal: Profit **26%** Up, USFDA Inspection Mein Bhi Clean Chit!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorKavya Nair|Published at:
Torrent Pharma Ki Q3 Kamaal: Profit **26%** Up, USFDA Inspection Mein Bhi Clean Chit!
Overview

Torrent Pharma ke investors ke liye aaj ka din super raha! Company ne Q3 FY26 mein apna net profit **26.3%** badha kar **₹635 Crore** kar liya hai. Revenue bhi **17.6%** jump karke **₹3,303 Crore** ho gaya. Aur sabse badi baat, USFDA ne unki Bileshwarpura plant ko zero observations ke saath clear kar diya hai, jo US market access ke liye bohot important hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

USFDA Inspection Mein Clean Chit Mil Gayi!

Gujarat mein Torrent Pharma ki Bileshwarpura (Oncology) facility ko April 6 se April 10, 2026 tak USFDA ne inspect kiya tha. Aur khushkhabri yeh hai ki zero observations mili! Matlab plant global standards ko fulfill karta hai. Ye approval US jaise bade market mein access ke liye bohot zaroori hai, especially jab regulatory scrutiny badh rahi hai.

Company Ke Numbers Bhi Zor Daar Hain!

Financials ki taraf dekhein toh EBITDA bhi 19% badh kar ₹1,088 Crore pahunch gaya. Margins 32.9% par stable hain. USFDA ki clean chit ke baad US business mein continuous growth ki umeed hai.

India Aur Brazil Mein Bhi Dhamaka!

Company ne local markets mein bhi kamaal kar dikhaya. India mein revenue 14% badha, ₹1,798 Crore tak pahuncha, jo overall Indian Pharmaceutical Market (IPM) growth (10%) se kaafi aage hai. Cardiac, gastro, aur diabetes therapies ne yahan lead kiya. Brazil mein toh revenue 27% bhaga, ₹371 Crore tak pahuncha, market growth (7%) ko peeche chhod diya. US mein bhi revenue 19% badhi, ₹321 Crore ho gayi.

Valuation Aur Peers Ka Comparison

Torrent Pharma ka market cap lagbhag ₹1.40 lakh Crore hai. Iska P/E ratio 60x-72x hai, jo Lupin (22.7x) aur Dr. Reddy's (17.6x) jaise competitors se kafi high hai. Sun Pharma aur Cipla bhi isse kam P/E par hain. Ye premium valuation dikhata hai ki investors ko company ke future growth aur regulatory track record par bharosa hai.

Aage Kya Challenges Hain?

Lekin bhai, challenges toh har sector mein hote hain. US generics market mein price pressure aur raw material costs badhne se profitability par asar pad sakta hai. Company ko apna valuation maintain karne ke liye consistent growth aur koi regulatory issue nahi hone dena hai.

Analysts Kya Bol Rahe Hain?

Analysts kaafi optimistic hain. Unke according, Torrent Pharma ka annual earnings 21.3% aur revenue 24.3% tak grow kar sakta hai. Consensus rating 'BUY' hai aur 1-year price target ₹4,527 ke aas paas hai. Agla earnings report May 21, 2026 ko aayega.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.